Frontiers in Pediatrics (Jun 2024)

Glycodeoxycholic acid as alternative treatment in 3β-hydroxy-Δ5-C27-steroid-oxidoreductase: a case report

  • S. Majait,
  • F. M. Vaz,
  • F. M. Vaz,
  • F. M. Vaz,
  • E. Marleen Kemper,
  • A. H. Bootsma,
  • A. K. Groen,
  • M. Nieuwdorp,
  • Maarten R. Soeters

DOI
https://doi.org/10.3389/fped.2024.1418963
Journal volume & issue
Vol. 12

Abstract

Read online

Background3β-hydroxy-Δ5-C27-steroid-oxidoreductase (3β-HSD) deficiency is a bile acid synthesis disorder that leads to the absence of normal primary bile acids and the accumulation of abnormal bile acids. This results in cholestatic jaundice, fat-soluble vitamin deficiency, acholic or fatty stools and failure to thrive. Bile acid supplementation is used to treat 3β-HSD-deficiency and its symptoms.MethodsThis report details the case of a 28-year-old woman diagnosed with 3β-HSD-deficiency, who was treated with glycine-conjugated deoxycholic acid (gDCA).ResultsgDCA treatment successfully restored normal bile acid levels, improved body weight by reducing fat malabsorption, and was well-tolerated with no observed liver problems or side effects.ConclusionsAs a potent FXR ligand, gDCA might exert its action through FXR activation leading to bile acid synthesis regulation.

Keywords